Coherus Q2 LOQTORZI rev $10M (+36% QoQ); UDENYCA divestiture closed for $483M

Coherus Oncology, Inc.

2025-Q2 EPS reported $2.08 vs consensus -$0.30 ▲ beat (+787.4%)

LOQTORZI net revenue $10.0M in Q2 2025, up 36% from $7.3M in Q1 2025 and $3.8M in Q2 2024.
UDENYCA divestiture completed April 11, 2025; Coherus received $483.4M cash and is eligible for up to $75M milestones.
Used proceeds to repay substantially all $230M of 2026 Convertible Notes and buy out royalty rights for $47.7M.
Q2 2025 net loss from continuing ops $44.9M ($0.39 diluted loss) vs $54.9M ($0.48) YoY; non-GAAP net loss $39.0M.
Cash, cash equivalents and marketable securities $238M at June 30, 2025; CHS-114 and casdozokitug data readouts expected 1H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.